Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Notification That Annual Report Will Be Submitted Late (nt 10-k)
Date : 04/02/2018 @ 4:32PM
Source : Edgar (US Regulatory)
Stock : U.s. Stem Cell, Inc. (QB) (USRM)
https://ih.advfn.com/p.php?pid=nmona&article=77082951
Well done!
Investors are positioning themselves the last trading days.
We'll see what gives.
Everyone knows what's around the corner.
Let the traders chase it when we go up.
Not selling a single share!
Very nice upward trend.
When numbers are out I think we'll continue doing so.
To much news releases to come this spring and the rest of the year.
Keep those shares and be rewarded in the future!
March 15, 2018) - Bayhorse Silver Inc. (TSXV: BHS) ("Bayhorse" or the "Company") is pleased to report that Scandium values have been identified accompanying the high silver assays reported in its news release BHS2018-06, (March 6, 2018) from the Legend, Sunshine and Big Dog mineralized zones, Bayhorse Silver Mine, Oregon, USA.
The Scandium was identified during the assay resubmission that identified the gold values as reported in news release BHS2018-06. Preliminary metallurgical results indicate that Scandium can be recovered during the processing of the silver from the Bayhorse Silver Mine. Scandium (Sc) is a high value mineral used to produce high strength Aluminum alloys in the Aerospace Industry and is classed as a strategic mineral in the USA. The Company has submitted additional samples for metallurgical testing and recovery characteristics of the Scandium.
Scandium values are tabulated below:
Sample Type Sc g/t
BHS 1 Crosscut 7
BHS 2 Raise Legend 16
BHS 3 Legend 5
BHS 4 Legend 6
BHS 5 Legend 12
BHS 6 Shaft Legend 18
BHS 7 Legend 10
BHS 10 Shaft top 17
Sample Type Sc g/t
Shaft middle BHS 11 20
BHS 12 Shaft 21
Upper raise 11
Big Dog 20
Chip, Legend top 15
Channel Legend east 11
Chip, Legend west 24
Chip, Legend bottom 12
Chip, Legend top west 21
Chip, Legend west 22
BHS 21 Chip LZ 24
Sample Type Sc g/t
BHS 22 blast select 26
BHS 23 blast select 25
BHS 24 blast select 21
BHS 25 blast select 19
BHS 26 blast select 26
BHS 27 blast select 24
BHS 28 blast select 23
BHS 29 blast select 25
BHS 30 blast select 24
BHS 31 blast select 26
BHS 32 blast select 6
Sample Type Sc g/t
BHS 33 blast select LZ 6
BHS 34 blast select LZ 6
BHS 35 blast select LZ 14
BHS 36 blast select 16
BHS 37 blast select 22
BHS 38 blast select 14
Bayhorse CEO, Graeme O'Neill comments, " While the Scandium values reported would not be considered enough to make a Scandium mine, in the event they are economically recoverable, the Scandium is certainly a value added mineral to any silver recovery."
Yes HD, you are right.
This will be worth billions.
Isn't that in every stock when you think you are right?
It will come.
I think they should roll this out as soon as possible across the ocean. (Europe to start with?)
The market worldwide is very big.
But ok, first things first.
Everything looks great so far.
When the FDA finally approves this treatment we are definitely off to the races.
However, even without it we are doing outstanding! (revenues)
But I want this treatment to be available for everyone, it's changing the whole healthcare business in the near future.
USRM investors from the first hour will see improving PPS and in the end a big payout.
New investors that got in at ridiculous prices will make a ton of money.
I'm not selling a single share since I finally found a one of a lifetime opportunity to get a big payout as an investor.
You can make a lot wrong investments but you only need one good one to get a big payout that may change your life.
And it even feels better when everyone will have a better life because these treatments are available in the near future!!!
Not a parabolic move.
I's just the second wave to bout 50 cents.(possibly a bit further)
The first wave was to about 12 cents.
3th wave depends on high second wave I'd guess ; - ))
Power Hour today or a calm end of day / week?
Need Shares Tsunamitrader?
Just buy from the ask, that's all.
I don't care if they would delay...what's the problem with news next week instead of today?
Who cares?
I already did in anticipation on increasing revenues.
Buying cheaper means more shares per dollar, thus more profit later on.
I'm with rocket rider here.
Up to multiple dollars.
I bought yesterday and today.
These prices we will be laughing about in a year from now.
To much in the pipe.
USRM is a life-changer for some.
Have an order standing at 0,065
To bad it didn't go.
The daily chart looks great.
Higher highs, higher lows. The bottom seems in again.
Up to 12 cents for starters.
I'm still in the bid but not much has been offered so got 60% of my offer.
I could buy from the ask, but when there's news it will go on numbers like you described
When they are talking about 'an article' then that person will be losing credibility.
Sorry Billy
It doesn't matter what world economy and dow/nasdaq/other penny stocks are doing atm.
It just matters what USRM is doing, now and the rest of the year(s)
I think they will deliver every quarter so yeah, I agree mate.
Don't like to see Marketmakers playing it down down every time ..
No sellers.
Looks ok if you ask me.
thx prime
That it will shake things up is an understatement.
Agreed. SSOF is very interesting.
Indeed it's a reminder.
I think there is to much lined up with positive news over that period with increasing revenues and what more to come.
I'm holding 330k shares and won't be trading them at these lvl's.
Don't want to be on the sidelines.
In the back of my mind I keep my focus on the longer term where USRM can be life changing for some investors with a pretty small investment.
A buyout is ok, but only in the 5 dollar and higher region.
Otherwise I'd rather wait until the stock climbs to that lvl over a longer period.
USRM The best opportunity there is in the OTC sector;
A year ago:
March 15th 2017
Financial highlights from 2016 include:
Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015
April 13th 2017
“We see exponential growth in the stem cell industry, estimated to grow to $170 billion by 2020,” said Joseph DaGrosa, Jr., a Principal with General American Capital Partners. “We are very pleased to join forces with U.S. Stem Cell, Inc., a leader in regenerative medicine solutions, to help expand our role in this important market.” [/I]
a commitment to invest up to $5,000,000 from private equity firm General American Capital Partners LLC (GACP) in exchange for up to 63,873,275 shares of common stock.
Continued positive results Q1 May 3th 2017
Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.[/I]
And again August 9th 2017:
Revenue up by 104% year-over-year for the quarter: from $678K in Q2 2016 to 1.38M in Q2 2017
Revenue up by 83% YTD: from $1.39M this time last year to $2.54M in Q2 2017
Margin increased from 65% to 71% quarter-to-quarter
Gross profit up by 122% (or $542K) year-over-year for the quarter: from $442K in Q2 2016 to $985K in Q2 2017
Gross profit up by 80% (or $796K) YTD: from $999K this time last year to $1.79M in Q2 2017
Income from operations increased from a loss of ($259K) in Q2 2016 to a gain of $142K in Q2 2017, a three-month comparison
Income from operations increased YTD from a loss of ($272K) in Q2 2016 to a gain of $100K in Q2 2017, a six-month comparison
Cash Flow is positive YTD at Q2 2017 at $785K compared to YTD Q2 2016 at ($165K), a six-month comparison
Working Capital Deficit down 6.9% from $5.8M in Q2 2016 to $5.4M in Q2 2017[/I]
September 13th 2017 Lower Debt
Hunton agreement is part of U.S. Stem Cell, Inc.’s continued effort to clean up the balance sheet and lower the company’s debt. This agreement is estimated to provide a debt relief of approximately $393,180.
October 11th 2017
Dr Comellia;
“Our study demonstrates exceptional patient safety with low complication rates and underscores the safety of autologous stem cell therapy in general,”[/I]
November 1st 2017
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening of another regenerative clinic using its proprietary products and services, bringing the number of clinics using its technology to 287.
November 7th 2017
Again increasing revenues up 106 percent or $730k from the same quarter last year to $1.5m.
November 28th 2018
“We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless,” said Dr. Comella, who co-authored the study along with two colleagues. “We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one.”[/I]
2018
January 9th 2018
Just this line: On a Mission to Obtain Optimal Health from the Inside Out[/I]
The rest of Dr Comellia's writings: here
January 15th 2018
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell TM product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM’s proprietary stem cell products and services.[/I]
February 6th 2018
A News Release that I really like without seeing any numbers until today;
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
And the very latest from USRM March 21st 2018;
U.S. Stem Cell, Inc. a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells.[/I]
Today Sunday march 25th 2018 we are awaiting;
- results about revenues, continuing this year
- If the FDA is willing to continue to work with USRM to help define fair regulation for the public
regarding these therapies RMAT
- USRM is actively seeking strategic partners to pursue commercialization of the MyoCell product
A lot more to come and this will be the next generation; Stem cells that in the end will help us all.
Investors will profit from that as well but keep in mind that the whole process and it's progress is a benefit to us all as a human being!
USRM The best opportunity there is in the OTC area;
A year ago:
March 15th 2017
Financial highlights from 2016 include:
Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015
April 13th 2017
“We see exponential growth in the stem cell industry, estimated to grow to $170 billion by 2020,” said Joseph DaGrosa, Jr., a Principal with General American Capital Partners. “We are very pleased to join forces with U.S. Stem Cell, Inc., a leader in regenerative medicine solutions, to help expand our role in this important market.” [/I]
a commitment to invest up to $5,000,000 from private equity firm General American Capital Partners LLC (GACP) in exchange for up to 63,873,275 shares of common stock.
Continued positive results Q1 May 3th 2017
Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.[/I]
And again August 9th 2017:
Revenue up by 104% year-over-year for the quarter: from $678K in Q2 2016 to 1.38M in Q2 2017
Revenue up by 83% YTD: from $1.39M this time last year to $2.54M in Q2 2017
Margin increased from 65% to 71% quarter-to-quarter
Gross profit up by 122% (or $542K) year-over-year for the quarter: from $442K in Q2 2016 to $985K in Q2 2017
Gross profit up by 80% (or $796K) YTD: from $999K this time last year to $1.79M in Q2 2017
Income from operations increased from a loss of ($259K) in Q2 2016 to a gain of $142K in Q2 2017, a three-month comparison
Income from operations increased YTD from a loss of ($272K) in Q2 2016 to a gain of $100K in Q2 2017, a six-month comparison
Cash Flow is positive YTD at Q2 2017 at $785K compared to YTD Q2 2016 at ($165K), a six-month comparison
Working Capital Deficit down 6.9% from $5.8M in Q2 2016 to $5.4M in Q2 2017[/I]
September 13th 2017 Lower Debt
Hunton agreement is part of U.S. Stem Cell, Inc.’s continued effort to clean up the balance sheet and lower the company’s debt. This agreement is estimated to provide a debt relief of approximately $393,180.
October 11th 2017
Dr Comellia;
“Our study demonstrates exceptional patient safety with low complication rates and underscores the safety of autologous stem cell therapy in general,”[/I]
November 1st 2017
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening of another regenerative clinic using its proprietary products and services, bringing the number of clinics using its technology to 287.
November 7th 2017
Again increasing revenues up 106 percent or $730k from the same quarter last year to $1.5m.
November 28th 2018
“We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless,” said Dr. Comella, who co-authored the study along with two colleagues. “We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one.”[/I]
2018
January 9th 2018
Just this line: On a Mission to Obtain Optimal Health from the Inside Out[/I]
The rest of Dr Comellia's writings: here
January 15th 2018
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell TM product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM’s proprietary stem cell products and services.[/I]
February 6th 2018
A News Release that I really like without seeing any numbers until today;
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
And the very latest from USRM March 21st 2018;
U.S. Stem Cell, Inc. a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells.[/I]
Today Sunday march 25th 2018 we are awaiting;
- results about revenues, continuing this year
- If the FDA is willing to continue to work with USRM to help define fair regulation for the public
regarding these therapies RMAT
- USRM is actively seeking strategic partners to pursue commercialization of the MyoCell product
A lot more to come and this will be the next generation; Stem cells that in the end will help us all.
Investors will profit from that as well but keep in mind that the whole process and it's progress is a benefit to us all as a human being!
A year ago:
March 15th 2017
Financial highlights from 2016 include:
Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015
April 13th 2017
“We see exponential growth in the stem cell industry, estimated to grow to $170 billion by 2020,” said Joseph DaGrosa, Jr., a Principal with General American Capital Partners. “We are very pleased to join forces with U.S. Stem Cell, Inc., a leader in regenerative medicine solutions, to help expand our role in this important market.” [/I]
a commitment to invest up to $5,000,000 from private equity firm General American Capital Partners LLC (GACP) in exchange for up to 63,873,275 shares of common stock.
Continued positive results Q1 May 3th 2017
Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.[/I]
And again August 9th 2017:
Revenue up by 104% year-over-year for the quarter: from $678K in Q2 2016 to 1.38M in Q2 2017
Revenue up by 83% YTD: from $1.39M this time last year to $2.54M in Q2 2017
Margin increased from 65% to 71% quarter-to-quarter
Gross profit up by 122% (or $542K) year-over-year for the quarter: from $442K in Q2 2016 to $985K in Q2 2017
Gross profit up by 80% (or $796K) YTD: from $999K this time last year to $1.79M in Q2 2017
Income from operations increased from a loss of ($259K) in Q2 2016 to a gain of $142K in Q2 2017, a three-month comparison
Income from operations increased YTD from a loss of ($272K) in Q2 2016 to a gain of $100K in Q2 2017, a six-month comparison
Cash Flow is positive YTD at Q2 2017 at $785K compared to YTD Q2 2016 at ($165K), a six-month comparison
Working Capital Deficit down 6.9% from $5.8M in Q2 2016 to $5.4M in Q2 2017[/I]
September 13th 2017 Lower Debt
Hunton agreement is part of U.S. Stem Cell, Inc.’s continued effort to clean up the balance sheet and lower the company’s debt. This agreement is estimated to provide a debt relief of approximately $393,180.
October 11th 2017
Dr Comellia;
“Our study demonstrates exceptional patient safety with low complication rates and underscores the safety of autologous stem cell therapy in general,”[/I]
November 1st 2017
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening of another regenerative clinic using its proprietary products and services, bringing the number of clinics using its technology to 287.
November 7th 2017
Again increasing revenues up 106 percent or $730k from the same quarter last year to $1.5m.
November 28th 2018
“We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless,” said Dr. Comella, who co-authored the study along with two colleagues. “We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one.”[/I]
2018
January 9th 2018
Just this line: On a Mission to Obtain Optimal Health from the Inside Out[/I]
The rest of Dr Comellia's writings: here
January 15th 2018
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell TM product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM’s proprietary stem cell products and services.[/I]
February 6th 2018
A News Release that I really like without seeing any numbers until today;
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
And the very latest from USRM March 21st 2018;
U.S. Stem Cell, Inc. a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells.[/I]
Today Sunday march 25th 2018 we are awaiting;
- results about revenues, continuing this year
- If the FDA is willing to continue to work with USRM to help define fair regulation for the public
regarding these therapies RMAT
- USRM is actively seeking strategic partners to pursue commercialization of the MyoCell product
A lot more to come and this will be the next generation; Stem cells that in the end will help us all.
Investors will profit from that as well but keep in mind that the whole process and it's progress is a benefit to us all as a human being!
Thx!!!
Haha, yeah.
Didn't want to wait on a 0003 so went in with a first trance.
On next occasions I'll place a bid though.
Ok, just bought 4mill a second ago.
let's see what gives..
Not selling a share.
You all can do whatever you want but I don't want to trade for pocket change and suddenly being at the sidelines when there's big news.
Had that twice in the past, ouch. Not going to happen this time.
A slot shares in stronger hands.
All in all already a good day.
Let's see what power hour brings us today.
I'm loaded and biased.
Doesn't matter when but the price reflection will be way up from here.
It's really not possible to tell where we stand in 6 months from now.
One thing is for sure; the outcome will be good for investors, and more important, the patients.